NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
Clinical Trials
5 trialsNCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT04952753 2025-03-26
daNIS-3
Novartis
Phase 2 Terminated
NCT04924413 2024-07-03
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Henan Cancer Hospital
Phase 2 Terminated
NCT05176925 2024-01-29
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Fudan University
Phase 2 Terminated